Market research
0QIU.LSE Novo Nordisk A/S
LSE DKK Not available
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 20B
- P/E ratio
- 0.39
- Analyst target
- Not available
- Dividend yield
- 1.7%
- Beta
- 0.24
Profile
Company facts
- Exchange
- LSE
- Currency
- DKK
- Sector
- Not available
- Industry
- Not available
- ISIN
- DK0062498333
- Market cap
- 20B
- P/E ratio
- 0.39
- Analyst target
- Not available
- Dividend yield
- 1.7%
- Beta
- 0.24
About
About Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Visit company websiteCommunity
Investor discussion
0 comments
Sign in to join the 0QIU.LSE discussion.
No comments yet
Start a focused discussion about 0QIU.LSE.